Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
3360 participants
INTERVENTIONAL
2021-01-09
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Online Treatments for Mood and Anxiety Disorders in Primary Care
NCT01482806
Healthy Mood Internet Intervention Research Project
NCT01358487
Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas
NCT00012974
Computer-assisted Cognitive-Behavior Therapy for Depression in Primary Care
NCT02700009
Treatment of Post-TBI Depression
NCT00211835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This mismatch between treatment availability and preference is important because MDD remission increases substantially when patients are treated with their preferred type. There is thus good reason to believe that providing access to eCBT will improve MDD treatment outcomes in our trial. Indeed, prior controlled trials show that both types of eCBT the investigators will randomize yield significantly better outcomes than waiting list controls. Controlled trials also show that guided eCBT yields equivalent outcomes to telephone and face-to-face CBT, but at much lower cost. Other controlled trials show that combined CBT-ADM yield significantly better outcomes than either CBT-alone or ADM-alone, although these comparisons have been made only for face-to-face CBT. These results provide good reason to believe that offering eCBT in rural FQHCs throughout WV and KY could improve MDD outcomes. Existing research on eCBT in rural areas, while promising, has been limited, making the research the investigators propose important to provide actionable information for patients and other stakeholders. Results intend to inform decisions about whether to offer/use eCBT, with what level of guidance, and for whom.
Unguided eCBT is web-based CBT completed with computerized feedback but no clinician involvement after an initial orientation meeting. Guided eCBT is web-based CBT completed with a remote eCoach who communicates with the patient via email, text, and telephone. eCoaches also provide elements of remote collaborative care case management, such as encouraging ADM adherence, monitoring ADM side effects and treatment response, coordinating with the primary care physician (PCP), and facilitating specialty referral. Collaborative care is known to be highly effective in promoting MDD symptomatic remission. In addition, a study in Arkansas FQHCs found that remote collaborative care case management out-performed on-site case management in rural clinics too small to justify having a dedicated mental health case manager on staff. However, remote collaborative care case management often involves delivering telephone CBT. A major constraint on expanding the collaborative care model for primary care MDD treatment, which has been used in urban but not rural WV clinics, is lack of case managers who can deliver telephone CBT. Thus, expanding eCBT in rural WV would allow offering a strongly evidence-based form of patients' preferred treatment (psychotherapy) and a form of a well-validated rural MDD care model (collaborative care case management with guided eCBT) that cannot be offered currently because of limited clinical resources.
Given its documented efficacy and rapid spread, the investigators expect eCBT to become widely available in rural WV as a result of our trial. But two real-life decisional dilemmas will arise in that context. Primary care clinicians will be faced with the decision about when to recommend eCBT and at what level of intensity. Patients will be faced with the decision of whether to accept guided or unguided eCBT as part of their treatment plan. These are non-trivial decisions, as eCBT incurs a time cost, and guided eCBT incurs a financial cost and requires interactions with a supporter for patients who desire independence and privacy. Further, eCBT has the potential to harm, as when lack of engagement leads the patient to drop out of all treatment, including ADM, whereas that patient would have remitted with ADM. Our heterogeneity of treatment effects (HTE) analyses will examine which patients profit from guided eCBT, which do equally well or better with unguided than guided eCBT, and which do as well or better with ADM in the absence of eCBT. A good deal of research has been carried out on eCBT HTE, although not in conjunction with ADM. This research suggests that the value of eCBT for MDD varies considerably depending on diverse patient characteristics the investigators plan to study. As with the comparative effectiveness evidence for eCBT vs other MDD therapies, though, research on MDD HTE up to now has focused on narrowly-defined symptom outcomes. In addition, although more than two dozen consistently significant baseline patient-reported predictors of MDD HTE have been documented, no single study ever considered more than a handful of these predictors. In addition, past MDD HTE studies have been underpowered. Our analysis will be based on a sample of 3,360 patients powered to detect HTE in the entire sample. Our patient and provider partners have indicated that evidence about the prescriptive predictors of these differences will be of great value in their treatment selection decisions. The causal model underlying the design is drawn from previous studies reviewed here: that MDD remission of primary care patients can be increased by adding eCBT to treatment-as-usual (TAU) via mechanisms that include influencing cognitions and behaviors to promote psychological recovery and encouraging increased ADM compliance. This model underlies all aspects of our design (selection of population, interventions, measures, analytic methods, procedures for handling confounding, time frame).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Survey data collectors will be blinded to each participant's treatment arm.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Primary Care Treatment
The participant will receive treatment as usual as prescribed by the primary care physician for MDD.
No interventions assigned to this group
Primary care treatment with eCBT
The participant will receive treatment as usual as prescribed by the primary care physician with the addition of eCBT for MDD.
remote internet-based cognitive behavior therapy (eCBT)
Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
Primary care treatment with guided eCBT
The participant will receive treatment as usual as prescribed by the primary care physician with the addition of guided eCBT for MDD.
remote internet-based cognitive behavior therapy (eCBT)
Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
remote internet-based cognitive behavior therapy (eCBT)
Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. appropriate for outpatient treatment,
3. literate in English,
4. has access to a smart phone, home computer or willing to travel to access a computer
5. without hearing or vision or cognitive impairment that would interfere with research data collection
6. without history of either bipolar disorder or non-affective psychosis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Patient-Centered Outcomes Research Institute
OTHER
University of South Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert Bossarte
Professor, Department of Psychiatry and Behavioral Neuroscience
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Bossarte, PhD
Role: PRINCIPAL_INVESTIGATOR
University of South Florida
Ronald Kessler, PhD
Role: PRINCIPAL_INVESTIGATOR
Harvard Medical School (HMS and HSDM)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Lousiville Health
Louisville, Kentucky, United States
Upper Kanawha Clinic
Cedar Grove, West Virginia, United States
Minnie Hamilton Health Systems
Glenville, West Virginia, United States
Minnie Hamilton Health Systems
Grantsville, West Virginia, United States
Harpers Ferry Family Medicine
Harpers Ferry, West Virginia, United States
WVU Medicine
Morgantown, West Virginia, United States
Wayne Medical Clinic
Wayne, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bossarte RM, Kessler RC, Nierenberg AA, Chattopadhyay A, Cuijpers P, Enrique A, Foxworth PM, Gildea SM, Belnap BH, Haut MW, Law KB, Lewis WD, Liu H, Luedtke AR, Pigeon WR, Rhodes LA, Richards D, Rollman BL, Sampson NA, Stokes CM, Torous J, Webb TD, Zubizarreta JR. The Appalachia Mind Health Initiative (AMHI): a pragmatic randomized clinical trial of adjunctive internet-based cognitive behavior therapy for treating major depressive disorder among primary care patients. Trials. 2022 Jun 20;23(1):520. doi: 10.1186/s13063-022-06438-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCS-2017C3-9252
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.